A randomised clinical trial (RCT) published in The Lancet has evaluated whether a structured behavioural intervention to promote fluid intake reduces recurrent urinary stone events in patients with a history of nephrolithiasis. After a two-year follow-up period, the intervention did not demonstrate a statistically significant reduction in stone recurrence compared with guideline-based care, though it did produce a modest increase in urine output among participants.

Background and Rationale

Urinary stone disease affects an estimated 10 to 12 percent of individuals in high-income countries, with recurrence rates approaching 50 percent within five years of an initial event. Current clinical guidelines consistently recommend increased fluid intake, targeting a urine volume exceeding 2.0 to 2.5 litres per day, as a first-line measure for secondary prevention. The recommendation is grounded in physiological rationale: dilution of urinary solutes reduces supersaturation of lithogenic compounds including calcium oxalate, calcium phosphate, and uric acid, thereby attenuating the conditions that favour crystal nucleation and growth.

Despite the mechanistic plausibility of high fluid intake as a preventive strategy, adherence to hydration recommendations in routine clinical practice remains poor. Patients typically receive brief, verbal instruction at the point of care, with little structured support thereafter. The gap between guideline recommendation and patient behaviour represents a persistent challenge in urologic and nephrologic management. The investigators of this trial sought to address that gap by testing whether a formal adherence intervention, designed using principles of behavioural science, could translate the hydration recommendation into a clinically meaningful reduction in stone recurrence.

Trial Design

The study was structured as a parallel-group, open-label RCT. Participants were adults with at least one prior urinary stone event who were assigned to either a behavioural adherence intervention or standard guideline-based care. The intervention arm received structured support intended to promote sustained increases in daily fluid consumption, incorporating strategies such as goal-setting, self-monitoring of urine output, and regular reinforcement through contact with study personnel. Specific components of the behavioural programme were designed to address common barriers to adherence, including inconvenience, forgetfulness, and insufficient awareness of personal hydration status.

The primary endpoint was time to first recurrent stone event during the two-year follow-up period, assessed through a composite of symptomatic stone passage, radiologically confirmed stone growth, and surgical stone-related intervention. Secondary endpoints included change in 24-hour urine volume, urinary solute concentrations, and patient-reported adherence to fluid intake targets.

Primary Findings

The trial did not identify a statistically significant difference in the rate of recurrent stone events between the intervention and control arms over the two-year observation period. The hazard ratio and associated confidence interval were consistent with an absence of a clinically meaningful effect on the primary composite endpoint, with the p-value failing to reach the pre-specified threshold for statistical significance.

The absence of a detectable effect on stone recurrence is notable given that the intervention did succeed in modifying the target behaviour. Participants assigned to the adherence programme demonstrated a modest but measurable increase in 24-hour urine volume relative to those receiving guideline-based care alone. This finding establishes that the behavioural intervention achieved partial success at the intermediate level, namely, shifting fluid intake behaviour, without that shift translating into the anticipated downstream clinical benefit.

Interpreting the Null Result

The dissociation between improved urine volume and unchanged stone recurrence rates warrants careful consideration. Several interpretive frameworks merit examination.

First, the magnitude of the increase in urine output achieved in the intervention arm may have been insufficient to produce a measurable effect on recurrence within a two-year window. The mineralogical conditions that promote stone formation operate over extended time periods, and trials of this duration may lack adequate power to detect prevention signals for an outcome with the natural variability characteristic of nephrolithiasis recurrence.

Second, the composite primary endpoint incorporated heterogeneous components, including symptomatic events and radiological findings, which carry different clinical weights and may respond differentially to hydration-mediated changes in urinary chemistry. Recurrent stone growth detectable on imaging does not necessarily correlate with symptomatic burden or require intervention, and its inclusion in a composite endpoint may dilute the signal from clinically meaningful events.

Third, patient selection may have introduced a ceiling effect. Participants enrolled in an RCT focused on stone prevention may represent a group already more motivated than the general stone-forming population, potentially reducing the contrast between intervention and control arms at baseline. If participants in the guideline-based care group also improved their hydration behaviours as a result of enrolment and regular follow-up contact, the effective difference in urine volume between groups may have been attenuated.

Fourth, it bears consideration that fluid intake may be a necessary but not sufficient component of secondary stone prevention for many patients. Stone-forming tendency is heterogeneous across individuals, with contributions from urinary calcium excretion, oxalate metabolism, citrate levels, and anatomical factors. A hydration intervention targeting urine volume alone may produce limited benefit in patients whose recurrence risk is primarily driven by metabolic or structural factors rather than urinary supersaturation modifiable by dilution.

Methodological Considerations

The open-label design of the trial, while essentially unavoidable in a behavioural intervention study, introduces the possibility of performance and detection bias. Participants aware of their assignment to an active intervention may report behaviours differently or engage differently with follow-up assessments. Objective measures, including 24-hour urine collections, partially mitigate this concern, though compliance with urine collection itself introduces measurement uncertainty.

The two-year follow-up duration, while reasonable for a funded RCT, may be insufficient to capture the full effect of hydration behaviour change on stone recurrence. Observational data suggest that the protective effect of sustained high fluid intake may require longer periods to manifest across a population, particularly in individuals whose stone-forming tendency is low to moderate at baseline. Longer follow-up with continued intervention support would be necessary to address this limitation.

The generalisability of the findings also merits attention from the perspective of Hawaii Medical Journal’s readership. Native Hawaiian and Pacific Islander populations carry a disproportionate burden of conditions associated with urinary stone disease, including obesity, type 2 diabetes, and dietary patterns associated with high urinary uric acid and oxalate excretion. Climate and occupational exposure to heat in Hawaii and across the Pacific region further elevate the risk of dehydration-related urinary concentration. The trial population was not described in the source material as enriched for Pacific Islander participants, and the behavioural intervention, which relied on specific goal-setting and monitoring frameworks, may require cultural adaptation to be effective in these communities. Clinical programmes targeting stone prevention in Hawaii should not assume direct transferability of the intervention as studied.

Implications for Clinical Practice

The null result on the primary endpoint does not invalidate the mechanistic basis for recommending high fluid intake in stone prevention. The physiological rationale remains sound, and prior observational evidence supports an association between higher urine output and reduced stone recurrence. The trial’s contribution is to establish that a particular behavioural intervention model, delivered over two years, did not produce the clinical effect anticipated from that mechanistic rationale at the population level studied.

For clinicians managing patients with recurrent nephrolithiasis, the findings reinforce several practical points. Fluid intake counselling remains appropriate as a component of secondary prevention, consistent with existing guideline recommendations. However, the expectation that structured behavioural support alone will substantially reduce stone recurrence should be tempered. Comprehensive metabolic evaluation, including 24-hour urine stone risk panels, continues to offer the advantage of identifying specific urinary abnormalities amenable to targeted dietary or pharmacological intervention. In patients with hypercalciuria, hyperoxaluria, or hypocitraturia, addressing those specific defects through dietary modification or appropriate pharmacotherapy provides a more directed strategy than hydration counselling in isolation.

The trial’s findings also have implications for how investigators design future studies in this area. The intermediate success of the behavioural intervention in increasing urine volume, without corresponding improvement in the primary clinical endpoint, suggests that future trials should consider longer follow-up periods, larger sample sizes to accommodate the event rates observed, and stratification of participants by metabolic stone risk profile. Trials that enrich for patients whose primary recurrence driver is urinary supersaturation modifiable by volume, rather than those with significant metabolic abnormalities, may be better positioned to detect a hydration effect on recurrence.

Conclusion

This RCT represents a rigorously designed attempt to translate an established but poorly implemented guideline recommendation into clinical benefit through structured behavioural support. The intervention modestly increased urine volume, confirming partial behavioural efficacy, but did not reduce recurrent urinary stone events over two years of follow-up. The results underscore the complexity of translating intermediate physiological targets into measurable reductions in a clinically variable outcome such as nephrolithiasis recurrence. Fluid intake promotion should continue as a component of stone prevention counselling, but clinicians should incorporate comprehensive metabolic risk assessment and targeted intervention as the primary framework for managing patients at risk for recurrent urinary stone disease.